A large prospective study published in Nature Communications on July 18 has quantified, for the first time in children, exactly how antibody levels correlate with the risk of SARS-CoV-2 infection. The findings offer a biological measure that could guide booster timing, variant-specific vaccine updates, and risk assessment as the virus continues to evolve.
The study, part of the CASCADIA project, enrolled 1,509 children aged 6 months to 17 years in Oregon and Washington, tracking them with weekly PCR tests and periodic blood sampling from June 2022 through 2024. The design is important: unlike most prior correlates-of-protection studies conducted in controlled vaccine trial settings, CASCADIA captures real-world conditions during Omicron circulation, across diverse immune histories.
What the Study Found
The researchers measured binding antibody titers (anti-nucleocapsid and anti-spike) and neutralizing antibody titers against Omicron sublineages BA.4/5 and XBB. Higher antibody levels consistently predicted lower infection risk across all pediatric age groups, regardless of whether immunity came from vaccination, prior infection, or both.
The strongest correlate was the level of nucleocapsid-binding antibodies, those generated by natural infection rather than by spike-only vaccines. Every 10-fold increase in anti-nucleocapsid antibody levels was associated with approximately a 40% reduction in infection risk. Omicron-specific neutralizing antibodies were the next strongest correlate. Spike-binding antibodies, which are induced by both vaccination and infection, provided more modest protection, around a 13-20% risk reduction per 10-fold increase.
The findings held for both overall infection risk and symptomatic infection risk, and were consistent across young children, school-age children, and adolescents.
Why Nucleocapsid Antibodies Matter Most
The finding that anti-nucleocapsid (anti-N) antibodies, which are only produced after actual infection, not by spike-only mRNA vaccines, are the most protective marker has practical implications. It suggests that hybrid immunity from combined vaccination and prior infection provides more robust protection than vaccination alone, and that anti-N levels could serve as a clinical tool for identifying children at higher risk of breakthrough infection.
The study also reinforces that protection is not binary but graded: higher antibody levels, regardless of their source, correlate with lower risk. This is consistent with the concept that the immune system’s memory is quantitative, not a simple yes-or-no.
Caveats
The study measured only humoral immunity, antibodies in the blood. It did not assess T-cell responses, B-cell memory, or mucosal IgA, all of which are known to play important roles in protection, particularly against severe disease. The findings are observational, not from a randomized trial, and come from a single geographic region during the Omicron era. The results may not hold for future, more immune-evasive variants.
Several co-authors reported industry ties with Pfizer, Moderna, Sanofi, AstraZeneca, Merck, and GSK, among others.
What It Means for Policy
With SARS-CoV-2 now a permanent endemic virus, understanding who is at risk and when has become a public health question rather than an emergency response. For children, who have generally faced lower risk of severe disease than adults, the question has shifted to: how often should they be boosted, and with what?
The CASCADIA immune correlates provide quantitative data for answering that question. If a child’s anti-N or neutralizing antibody levels fall below a certain threshold, their risk of infection rises sharply. Measurable thresholds could inform personalized booster recommendations, particularly for children with underlying conditions.
Sources
1. K.L. Hoffman, G. Marshall, C. Frivold, Z. Acker, I.S. Arnould, et al., “Immune Correlates of Risk for SARS-CoV-2 Infection in Children: A Prospective, Community-Based Cohort Study,” Nature Communications (2026). DOI: 10.1038/s41467-026-74684-8
2. CASCADIA study consortium, University of Washington / Seattle Children’s Research Institute / Kaiser Permanente Northwest / Fred Hutchinson Cancer Center / CDC.